Investor's Business Daily on MSN
GSK is eyeing $55 billion in sales — and it has nothing to do with obesity
GSK stock catapulted Wednesday after the UK-based drugmaker said it expects sales in five years' time to approach $55 billion ...
If you are wondering whether GSK shares offer good value right now, you are not alone, especially with the stock firmly back ...
Analysts at JP Morgan raised their target price on drugmaker GSK to £22.50 on Monday on improving investor perception.
Zacks Investment Research on MSN
Why GSK (GSK) is a top value stock for the long term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...
GSK plc reports fourth-quarter earnings Wednesday, marking the first results under new Chief Executive Luke Miels as the ...
New boss Luke Miels knows perils of overpromising but there is growing sense pharma firm is closer to filling potential ...
Shares of GSK PLC GSK dropped 1.77% to £21.59 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.16% to 10,386.23. GSK PLC ...
GSK's Nucala (mepolizumab) has received European Commission approval as an add on maintenance treatment for uncontrolled COPD. The approval is supported by positive Phase III MATINEE trial results.
GSK plc (NYSE:GSK) and Spero Therapeutics Inc (NASDAQ:SPRO) on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) ...
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results